Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 1:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 678 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Serum Collection Clear all
Terminated No phase listed Observational Results available

A Cohort Study of Operationally Tolerant Allograft Recipients

NCT02743793
View directory record Official record
Conditions
Kidney Transplant, Liver Transplant
Interventions
Blood Draw
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
5
States / cities
San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Nov 1, 2026, 1:15 AM EDT
Completed Phase 2 Interventional

Cariprazine for Comorbid Cocaine and Opioid Use Disorder

NCT05063201
View directory record Official record
Conditions
Opioid-use Disorder, Cocaine Use Disorder
Interventions
Cariprazine 1.5 MG, Placebo
Drug
Lead sponsor
Kyle Kampman
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Nov 1, 2026, 1:15 AM EDT
Withdrawn Phase 1 Interventional

Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung

NCT05717140
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Lung, Metastatic Melanoma, Recurrent Melanoma, Unresectable Melanoma
Interventions
Aerosol Sargramostim, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Medical Device Usage and Evaluation, Nivolumab
Biological · Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Nov 1, 2026, 1:15 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Autoimmune Basis for Postural Tachycardia Syndrome

NCT02725060
View directory record Official record
Conditions
Postural Orthostatic Tachycardia Syndrome, Postural Tachycardia Syndrome, Tachycardia, Arrhythmias, Cardiac, Autonomic Nervous System Diseases, Orthostatic Intolerance, Cardiovascular Diseases, Primary Dysautonomias
Interventions
phenylephrine, isoproterenol, 25 micro-Ci of radiation, Posture study with blood samples, 24-hour heart rhythm and blood pressure monitoring, Quantitative Axonal Sudomotor Reflex Testing, Autonomic function tests, Rebreathing test, Assessment of splanchnic capacitance, microneurography
Drug · Radiation · Procedure + 1 more
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Nov 1, 2026, 1:15 AM EDT
Withdrawn Early Phase 1 Interventional

Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124

NCT03087968
View directory record Official record
Conditions
Severe Alcoholic Hepatitis
Interventions
GS-4997, Prednisolone, HepQuant SHUNT Test, Placebo
Drug · Device
Lead sponsor
HepQuant, LLC
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
13
States / cities
Coronado, California • Miami, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Nov 1, 2026, 1:15 AM EDT
Active, not recruiting Phase 1 Interventional

NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

NCT04930783
View directory record Official record
Conditions
Melanoma, Metastatic Melanoma
Interventions
CDX-301, NEOVAX, Nivolumab, Pembrolizumab
Drug · Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Nov 1, 2026, 1:15 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Analytical Validation of the abioSCOPE Device With an IgE Test Panel: Point-of-Care Precision, Sample Type Comparison and Method Correlation

NCT04401631
View directory record Official record
Conditions
Allergy, Allergic Asthma, Allergy to Cats, Allergy to House Dust, Allergy to Dog Dander (Finding), Allergy Mold, Allergy Cockroach
Interventions
Blood Collection
Device
Lead sponsor
Abionic SA
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Nov 1, 2026, 1:15 AM EDT
Suspended Phase 2 Interventional

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

NCT06325683
View directory record Official record
Conditions
Progressive Glioblastoma, Recurrent Glioblastoma
Interventions
Biopsy Procedure, Biospecimen Collection, Lomustine, Magnetic Resonance Imaging, Nivolumab, Relatlimab, Surgical Procedure
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
325
States / cities
Jonesboro, Arkansas • Auburn, California • Duarte, California + 252 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 1, 2026, 1:15 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Identification of Epidermal Signatures in Patients With Atopic Dermatitis

NCT02680405
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Skin Biopsy, Skin tape stripping, Blood draw
Procedure
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Nov 1, 2026, 1:15 AM EDT
Completed Phase 2 Interventional

HEAL STUDY (Hepatic Encephalopathy and Albumin Study)

NCT03585257
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy, Minimal Hepatic Encephalopathy, Covert Hepatic Encephalopathy
Interventions
25% IV albumin, Placebo
Biological · Other
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Nov 1, 2026, 1:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Determining Normal Range for Free Light Chains in Serum Among Twins

NCT04191057
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Free light chains
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Nov 1, 2026, 1:15 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias

NCT00061568
View directory record Official record
Conditions
Congenital Hemolytic Anemia, Sickle Cell Disease
Interventions
Peripheral blood hematopoietic progenitor cell (PBPC) transplant, Alemtuzumab, Peripheral blood hematopoietic progenitor cell Apheresis, Sirolimus
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 80 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Nov 1, 2026, 1:15 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

The Testosterone Trials in Older Men

NCT00799617
View directory record Official record
Conditions
Andropause
Interventions
AndroGel® (testosterone gel), Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
65 Years and older · Male only
Enrollment
790 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2018
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Nov 1, 2026, 1:15 AM EDT
Completed No phase listed Observational

Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy

NCT01982591
View directory record Official record
Conditions
Male Breast Cancer, Neurotoxicity, Peripheral Neuropathy, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
laboratory biomarker analysis, questionnaire administration
Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Paoli, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Nov 1, 2026, 1:15 AM EDT
Not listed No phase listed Observational

Validating 4Ts for Heparin Induced Thrombocytopenia (HIT)

NCT00946400
View directory record Official record
Conditions
Heparin-Induced Thrombocytopenia
Interventions
Scoring 4Ts and Chong scale, Blood draw
Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 27, 2009 · Synced Nov 1, 2026, 1:15 AM EDT
Completed Phase 1Phase 2 Interventional

Fibrosis and the Fontan

NCT04901975
View directory record Official record
Conditions
Single-ventricle
Interventions
Spironolactone
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Year to 6 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Nov 1, 2026, 1:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of the Safety and Immunogenicity of NasoVAX Extension

NCT03760549
View directory record Official record
Conditions
Influenza
Interventions
Subjects were administered NasoVAX high dose
Drug
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Nov 1, 2026, 1:15 AM EDT
Recruiting Phase 2 Interventional

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

NCT06769126
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype, Lung Small Cell Carcinoma, I Subtype, Lung Small Cell Carcinoma, N Subtype, Lung Small Cell Carcinoma, P Subtype
Interventions
Biospecimen Collection, Ceralasertib, Computed Tomography, Durvalumab, Etoposide, Magnetic Resonance Imaging, Monalizumab, Platinum Compound, Positron Emission Tomography, Saruparib, Thoracic Radiation Therapy
Procedure · Drug · Biological + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
148
States / cities
Loma Linda, California • Rancho Mirage, California • Sacramento, California + 118 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Nov 1, 2026, 1:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Phase IV Trial to Collect Safety Data and Sera for Immunogenicity Testing in Healthy Children Given Fluzone® Vaccine

NCT00561002
View directory record Official record
Conditions
Influenza
Interventions
2007-2008 Influenza Virus Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 35 Months
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Nov 1, 2026, 1:15 AM EDT
Completed Phase 4 Interventional Results available

IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA

NCT02451748
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Lab Work, Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg), Certolizumab pegol (CDP870, tradename Cimzia), Hydroxychloroquine, Sulfasalazine, Medrol, Prednisone, Triamcinolone, Naproxen, Leflunomide, Methotrexate, humira
Other · Drug
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Nov 1, 2026, 1:15 AM EDT
Recruiting Phase 2 Interventional

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

NCT06532279
View directory record Official record
Conditions
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Stage 0 Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage 0 Hypopharyngeal Carcinoma AJCC v8, Stage 0 Nasopharyngeal Carcinoma AJCC v8, Stage 0 Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage I Hypopharyngeal Carcinoma AJCC v8, Stage I Laryngeal Cancer AJCC v8, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage I Nasopharyngeal Carcinoma AJCC v8, Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage II Hypopharyngeal Carcinoma AJCC v8, Stage II Laryngeal Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Stage II Nasopharyngeal Carcinoma AJCC v8, Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Nasopharyngeal Carcinoma AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stomatitis
Interventions
Best Practice, Biospecimen Collection, Cisplatin, Computed Tomography, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, MnSOD Mimetic BMX-001, Placebo Administration, Questionnaire Administration
Other · Procedure · Drug + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
153
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Nov 1, 2026, 1:15 AM EDT
Recruiting Phase 2 Interventional

Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder

NCT05786040
View directory record Official record
Conditions
Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Rituximab, Tafasitamab
Procedure · Biological
Lead sponsor
Timothy Voorhees
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
New Brunswick, New Jersey • Hillsborough, North Carolina • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Nov 1, 2026, 1:15 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Blood Donation Study for ALPCO Syphilis-T and Syphilis-NT Assay Development

NCT07830550
View directory record Official record
Conditions
Healthy Volunteers, Syphilis Serologic Assay Development, Blood Specimen Collection, Diagnostic Assay Development, Serum Specimen Collection
Interventions
ALPCO Syphilis-T, ALPCO Syphilis-NT CLIA Kits
Device
Lead sponsor
American Laboratory Products Company
Industry
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Salem, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Nov 1, 2026, 1:15 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Prospective Case-Control Study of Cardiovascular Changes in Pregnancy Related Hypertensive Disorders

NCT04713228
View directory record Official record
Conditions
Pre-Eclampsia
Interventions
ARTSENS Pen
Device
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Nov 1, 2026, 1:15 AM EDT